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AbstrACt
background Tumor- infiltrating lymphocytes (TILs), 
mainly CD8+ cytotoxic T lymphocytes (CTL), are linked to 
immune- mediated control of human cancers and response 
to immunotherapy. Tumors have nonetheless developed 
specific mechanisms that selectively restrict T cell entry 
into the tumor microenvironment. The extracellular 
superoxide dismutase (SOD3) is an anti- oxidant enzyme 
usually downregulated in tumors. We hypothesize that 
upregulation of SOD3 in the tumor microenvironment 
might be a mechanism to boost T cell infiltration by 
normalizing the tumor- associated endothelium.
results Here we show that SOD3 overexpression in 
endothelial cells increased in vitro transmigration of naïve 
and activated CD4+ and CD8+ T cells, but not of myeloid 
cells. Perivascular expression of SOD3 also specifically 
increased CD4+ and CD8+ effector T cell infiltration into 
tumors and improved the effectiveness of adoptively 
transferred tumor- specific CD8+ T cells. SOD3- induced 
enhanced transmigration in vitro and tumor infiltration 
in vivo were not associated to upregulation of T cell 
chemokines such as CXCL9 or CXCL10, nor to changes 
in the levels of endothelial adhesion receptors such as 
intercellular adhesion molecule-1 (ICAM-1) or vascular cell 
adhesion molecule-1 (VCAM-1). Instead, SOD3 enhanced 
T cell infiltration via HIF-2α-dependent induction of 
specific WNT ligands in endothelial cells; this led to WNT 
signaling pathway activation in the endothelium, FOXM1 
stabilization, and transcriptional induction of laminin-α4 
(LAMA4), an endothelial basement membrane component 
permissive for T cell infiltration. In patients with stage II 
colorectal cancer, SOD3 was associated with increased 
CD8+ TIL density and disease- free survival. SOD3 
expression was also linked to a T cell–inflamed gene 
signature using the COAD cohort from The Cancer Genome 
Atlas program.
Conclusion Our findings suggest that SOD3- induced 
upregulation of LAMA4 in endothelial cells boosts selective 
tumor infiltration by T lymphocytes, thus transforming 
immunologically “cold” into “hot” tumors. High SOD3 
levels are associated with human colon cancer infiltration 
by CD8+ T cells, with potential consequences for the 
clinical outcome of these patients. Our results also uncover 
a cell type–specific, distinct activity of the WNT pathway 
for the regulation of T cell infiltration into tumors.
bACkground
In many cancers, the density of tumor- 
infiltrating lymphocytes (TILs) determines 
immune- mediated control of tumor progres-
sion. The presence of TIL, mainly CD8+ cyto-
toxic T lymphocytes, correlates with disease 
outcome and response to immunotherapy.1–4 
The lack of T cell–based tumor inflammation 
is nevertheless a frequent event in primary 
cancers,5 which suggests there are specific 
mechanisms that selectively restrict T cell 
entry into the tumor microenvironment 
(TME).
In some cases, T cells are excluded from 
tumors through neoplastic- cell- intrinsic 
mechanisms6; of these, the best characterized 
is the aberrant activation of the canonical 
WNT/β-catenin pathway.7 This pathway relies 
on WNT- induced stabilization and nuclear 
translocation of β-catenin (catenin beta-1, 
CTNNB1), a dual- function protein involved 
in cell–cell adhesion and transcriptional 
regulation.8 Many human cancers, particu-
larly colorectal cancers (CRCs), show hyper-
activation of the WNT pathway owing to WNT 
ligand production, or mutations of WNT 
regulatory elements such as adenomatous 
polyposis coli or other elements of the β-cat-
enin “destruction complex”.7 In mouse 
models, β-catenin restricts TIL by impairing 
C- C motif chemokine ligand 4 (CCL4)–
induced recruitment of CD103+ dendritic 
cells that produce C- X- C motif chemokine 
ligand 9 (CXCL9) and CXCL10, which are 
suggested to be dominant for T cell recruit-
ment into tumors.9 Integrative analyses from 
TCGA datasets associated WNT/β-catenin 
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pathway activation with a non- T cell–inflamed signature 
across many different human cancers.5 Nonetheless, 
tumor stroma production of a natural antagonist of the 
WNT pathway has been associated to enhanced infiltra-
tion by immune suppressor cells and tumor growth.10
In other cases, T cells are excluded from tumors by 
tumor cell- extrinsic mechanisms. Among these, the 
dysfunctional vasculature has emerged as an important 
factor in the generation of an immunosuppressive TME 
by multiple mechanisms.11 To enter the tumor, immune 
cells must cross an endothelial cell (EC) barrier, a process 
that requires a coordinated sequence of adhesive inter-
actions involving selectins, integrins, various diapedesis 
receptors, and chemokines.12 They must also cross the 
endothelial basement membrane (BM), a largely over-
looked obstacle, although BM crossing is a limiting step 
in leukocyte infiltration into tissues.13 14 The endothelial 
BM components include the laminins, a family of hetero-
trimeric T- shaped glycoproteins with a variety of adhesive 
and stimulatory functions.15 Laminins have overlapping 
as well as specific functions due to their alpha chains. 
This is exemplified by laminin-8 (α4β1γ1) and laminin-10 
(α5β1γ1), the two predominant isoforms in vascular 
BM.15 Laminins bearing the α4 subunit (LAMA4) are 
associated to BM maturation and structural integrity of 
microvessels,16 and have been linked to permissive signals 
for transendothelial T cell migration17 18; in contrast, 
α5- containing laminins inhibit T cell transmigration.19 20 
How these laminin α-subunits affect TIL density has not 
been studied.
Another intriguing question is whether vascular 
normalization induced by strategies other than blockade 
of angiogenic factors would trigger TIL in the TME. To 
address this issue, we took advantage of the recent finding 
that expression of extracellular superoxide dismutase 
(SOD3) in the TME improves tumor- associated vascula-
ture function.21 SOD3 regulates the tissue redox balance 
by scavenging the ·O2
− anion,22 preventing oxidative 
damage of macromolecules and also preserving nitric 
oxide availability in the perivascular space. SOD3 normal-
izes tumor vasculature through specific stabilization of 
hypoxia- inducible factor (HIF)−2α, which then upregu-
lates VE- cadherin (VEC) transcription, in turn reducing 
vascular leakage and increasing tumor perfusion.21 SOD3 
is downregulated in a number of malignancies, including 
breast, lung, pancreas, and colorectal carcinomas.23–26 
Whether SOD3 influences T cell trafficking into tumors 
is not known.
Here, we show that SOD3 induces a permissive signal 
in EC that selectively enhances transendothelial migra-
tion of effector T cells, but not of myeloid or regulatory T 
(Treg) cells into tumors. SOD3 levels are also associated 
with increased CD8+ TIL density and improved clinical 
outcome in patients with stage II CRC. SOD3 enhances 
T cell transmigration through an EC- autonomous mech-
anism that involves the HIF-2α-induced upregulation of 
specific WNT ligands. This in turn triggers the FoxM1- 
induced LAMA4 upregulation in EC, which supplies a 
permissive signal for T cell transmigration. These find-
ings thus uncover a cell type–specific, distinct activity of 
the WNT pathway for the regulation of T cell infiltration 
into tumors, which could have clinical implications.
Methods
Detailed materials and methods are provided in online 
supplementary material.
human samples
A tissue microarray was constructed using 1 mm cores 
from 95 tumor blocks of stage II infiltrating large bowel 
carcinomas from the surgical pathology database of the 
Hospital Fundación Jiménez Díaz (Madrid, Spain). Two 
pathologists independently selected the most represen-
tative areas and reviewed histopathological features. For 
mRNA analyses, we used freshly frozen stages I–IV tumor 
samples (cohort 1) and formalin- fixed paraffin- embedded 
tumor samples from patients with stage III CRC (cohort 
2), both from the Hospital Clínico San Carlos Tumor 
Bank (Madrid, Spain).21 Appropriate informed consent 
was obtained from all patients and no personal data were 
registered.
Animals
C57BL/6J, Tg(TcraTcrb)1100Mjb/J (OT- I), Tg(TcraT-
crb)425Cbn/J (OT- II), and B6.Cg- Tg(Tek- cre)1Ywa/J 
(Tie2- Cre) mice were from The Jackson Laboratory (Bar 
Harbor, ME). SOD3−/− mice were kindly provided by 
Tim D. Oury (University of Pittsburgh, Pittsburgh, PA). 
SOD3EC- Tg mice were generated by crossing loxP- SOD3KI 
(SOD3Cre−) mice21 with Tie2- Cre transgenic mice. 
HIF-2αEC- KO mice were generated as described.21
Cell lines, overexpression, and silencing
The Lewis lung carcinoma (LLC; ATCC), the EG7- SOD3 
thymoma, and the murine microvascular 1G11- mock and 
1G11- SOD3 cell lines were cultured as described.21 27 The 
OVA- expressing EG7- SOD3 thymoma (and the control 
EG7- mock) were generated by retroviral transduction and 
selected by cell sorting (MoFlo XDP; Beckman Coulter) 
using GFP fluorescent emission. HIF-2α was overex-
pressed and silenced in 1G11 cells as described.21 Stable 
β-catenin mutant Δ90βcat overexpression was achieved by 
transfection with pCAG-Δ90- GFP (a gift of Anjen Chenn; 
Addgene no. 26645) and cells selected by cell sorting. For 
FoxM1 overexpression, 1G11 cells were transfected with 
pCMV6- Entry/FoxM1- Myc- DDK (Origene, MR210493) 
and clones selected by limiting dilution with neomycin 
(750 µg/mL; Apollo Scientific). For LAMA4 silencing, 
1G11- SOD3 cells were transfected with esiRNA targeting 
mouse LAMA4 (esiRNA1; Sigma- Aldrich; EMU083481) 
or a medium GC content siRNA duplex (Stealth RNAi 
siRNA Negative Control Med GC, 12935300; Invitrogen). 
For SOD3 overexpression in vivo, high- titer stocks of 
adenovirus expressing mouse SOD3 (Ad- SOD3) or β-ga-
lactosidase (Ad- C) were prepared as described.21
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syngeneic tumors and adoptive transfer
For all tumor models, female mice 2 to 5 months old 
were used. Exponentially growing LLC, EG7, or EG7- 
SOD3 cells were implanted subcutaneously in the indi-
cated mice. In experiments involving Doxo treatment, 
mice received intratumor Ad- mSOD3 or Ad- C viruses 
(109 pfu/50 µL) injections on days 7, 9, 11, and 15 post- 
implantation, and Vhcl or Doxo (2.5 mg/kg, intraperi-
toneally; Farmitalia Carlo Erba, Italy) on days 7, 11, and 
15. For in vivo WNT pathway inhibition, tumor- bearing 
mice were treated with XAV-939 or DMSO at days 5, 8, 
11, 12, and 13. In experiments involving HIF-2αEC- KO 
mice, tamoxifen (Sigma- Aldrich) was diluted in ethanol 
and corn oil, heated (100°C) and injected (1 mg/mouse, 
intraperitoneally) on days 3, 4, and 5 post- LLC or post- 
EG7- SOD3 inoculation. For some experiments, naïve 
or activated OT- I cells (107 cells/mouse, intravenously) 
were adoptively transferred to tumor- bearing mice (see 
online supplementary methods). Tumors were measured 
blind to treatment or genotype, and tumor volume 
calculated using the formula V=(width2×length)/2. For 
Kaplan- Meier curves, mice were considered “dead” when 
tumor volume >700 mm3. OT- I cell number was esti-
mated by FACS after staining with anti- Vα2- biotin, anti- 
Vβ5- PE, anti- CD45- BViolet570, and anti- CD8- eFluor450 
antibodies, followed by streptavidin–APC. In the other 
tumor models, immune infiltration was determined by 
immunohistochemistry.
Adhesion and transmigration assays
Adhesion and migration assays were performed with 
primary CD3+, CD4+, CD8+ T cells and CD11b cells 
isolated from the spleen of OT- II and OT- I mice by nega-
tive selection, using 10% fetal calf serum, CCL19 (250 ng/
mL; naïve T cells), CXCL10 (500 ng/mL; activated T 
cells), CCL2 (250 ng/mL; CD11b cells), or basal medium 
as chemoattractants.
mrnA quantification
Total RNA was extracted from mouse tumors and cell 
lines using TRI- Reagent (Sigma Aldrich) or RNeasy Mini 
or Micro Kit (Qiagen). RNA from human samples was 
extracted using TRIzol (Invitrogen) or RNeasy FFPE 
Kit (Qiagen), as described.21 mRNA levels were quanti-
fied by qPCR in an ABI PRISM 7900HT System (Applied 
Biosystems), using a SYBR EvaGreen- based reaction 
mix (5× PyroTaq EvaGreen qPCR Mix Plus ROX, Cmb- 
Bioline), with the primers listed in online supplementary 
table S1. β-Actin or CD31 (mouse samples) and RLP10A 
genes (human samples) were used for normalization. 
ChIP assays21 were performed with the Magna ChIP G 
(17-611; Merck Millipore). Each data point represented 
is the average of a technical triplicate in an independent 
experiment.
bioinformatic analyses
RSEM- normalized RNAseq expression data from 382 
CRC tumor samples were obtained from TCGA through 
the Firebrowse repository (http:// firebrowse. org/). A T 
cell inflammatory signature was computed as the average 
of the log expression values of 1346 genes.28
statistical analyses
Qualitative data are represented with percentages and 
absolute numbers, quantitative data as mean±SEM, unless 
otherwise indicated; individual values are also shown 
and the number of replicates is given in figure legends. 
For mouse studies, sample size was estimated using the 
power method and values corrected for 20% attrition. 
For human samples, cases were divided into negative and 
positive for SOD3 or LAMA4 staining using a receiver 
operating characteristic (ROC) curve approach. For data 
with a Gaussian distribution and homogeneity of vari-
ances, statistical significance was calculated with a two- 
tailed Student’s t- test, with the Welch correction when 
the number of replicas was low, for comparison of two 
independent groups, and one- way or two- way ANOVA 
with Dunnett’s, Tukey’s, or Bonferroni’s post hoc test for 
multiple comparisons. When these requirements were not 
fulfilled, data were analyzed using non- parametric tests. 
The potential associations between qualitative variables 
were analyzed with the χ2 test. Correlation analyses were 
performed using the non- parametric Spearman’s rank 
correlation coefficient. The outcome measure used for 
the human stage II cohort study was disease- free survival, 
defined as the time elapsed between surgical resection 
of the tumor with a curative intent and recurrence of 
disease in months. In the univariate analysis, Kaplan- 
Meier survival curves were compared with log- rank tests. 
SOD3 expression values were compared between T 
cell–inflamed and non- inflamed TCGA signatures using 
Student’s t- test. Differences were considered significant 
when p value <0.05. Statistical analyses were performed 
using the statistical package SPSS V.20.0 for Windows, 
and Prism software. All statistical tests were two sided.
results
sod3 increases t cell transmigration in vitro and in vivo
We analyzed the in vitro adhesion and transmigration of 
purified murine T (CD3+) and myeloid (CD11b+) cells 
through monolayers of mock- and SOD3- overexpressing 
1G11 cells, a mouse microvascular EC line modified to 
overexpress SOD3 (for overexpression data see21). SOD3 
overexpression in EC increased CD3+ T lymphocyte adhe-
sion and transmigration (figure 1A,B). This SOD3 effect 
was T cell specific, as it was not observed for myeloid 
CD11b+ cells, and applied for both naïve and ex vivo–acti-
vated CD4+ and CD8+ T cells (figure 1C,D).
To explore this selective SOD3 effect in vivo, we 
injected LLC cells into syngeneic immunocompetent 
mice; once tumors engrafted, mice received injections 
of adenoviruses expressing SOD3 (Ad- SOD3) to over-
express SOD3 in the TME, or β-galactosidase (Ad- C) as 
control, as verified by immunohistochemistry (IHC). In 
these conditions, SOD3 overexpression had no effect on 
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Figure 1 SOD3 selectively enhances T lymphocyte transmigration in vitro and in vivo. (A) Static adhesion of purified CD3+ T 
cells and CD11b+ myeloid cells to 1G11- mock and 1G11- SOD3 monolayers. Data shown as mean±SEM from a representative 
experiment (n=3). (B) CD3+ and CD11b+ cell transmigration through 1G11- mock or 1G11- SOD3 monolayers (n=7, 1G11- mock; 
n=9, 1G11- SOD3). (C) CCL19- induced transmigration of naïve CD4+ and CD8+ T cells through 1G11- mock or 1G11- SOD3 
monolayers (n=11, CD4+ cells; n=6, CD8+ cells). (D) Transmigration of OVA- activated OT- II (CD4+) and OT- I (CD8+) cells through 
1G11- mock or 1G11- SOD3 monolayers using CXCL10 as chemoattractant (n=5, 1G11- mock; n=6, 1G11- SOD3). (E) Scheme of 
the tumor model used; i.t., intratumor, i.p. intraperitoneal. (F) Growth kinetics of Ad- C- injected or Ad- SOD3- injected LLC tumors 
(n=4 mice/group). Arrows indicate treatment schedule with adenovirus (blue) and Doxo (green); a representative experiment is 
shown (n=2). (G) Kaplan- Meier survival curves for mice in (F). (H) CD3+ (green) and CD11b+ (red) cell infiltration into tumors from 
(F); nuclei were DAPI- stained (blue). (I) Quantification from (H) (n=8 fields; n=4 mice/group). (J) Ratio of tumor- infiltrating CD3+ 
and CD11b+ cells calculated from (H). (K) Ad- C- injected and Ad- SOD3- injected LLC tumor sections stained with anti- CD4+ 
(green) and anti- CD8+ (red) antibodies; nuclei were DAPI stained (blue). (L) Quantification from (K) (n=8 fields/condition; n=4 
mice/group). (M) FoxP3+ (green) and CD8+ (red) infiltrating cells in Ad- C or Ad- SOD3 LLC tumors; nuclei (blue). (N) Quantification 
from (M) (n=8 fields; n=4 mice/group). (O) FoxP3+:CD8+ ratio calculated in each image from (M). Mean±SEM are shown; each 
data point represents an individual measurement from at least three independent experiments (B–D) or from each mouse (I–K, 
M, N); *p<0.05, **p<0.01, two- tailed Student’s t-test.
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tumor growth or immune infiltrate (online supplemen-
tary figure S1).
We hypothesized that the absence of immunogenic 
stimulus in the aforementioned tumor model might 
limit T cell infiltration, precluding any SOD3 effect. To 
overcome this limitation, an immune response to LLC 
tumors was boosted by doxorubicin (Doxo) administra-
tion, which induces immunogenic cell death29; Ad- SOD3 
or Ad- C were then injected (figure 1E). Ad- SOD3- treated 
tumors showed reduced growth kinetics (figure 1F), 
which extended mouse survival (figure 1G). This was 
predicted, as SOD3 increases Doxo delivery into tumors.21 
Analysis of the immune infiltrate also indicated a specific 
increase in TIL number (CD3+) in Ad- SOD3- injected 
tumors compared with Ad- C controls (figure 1H,I), 
which resulted in an increased lymphoid:myeloid ratio 
(figure 1J). SOD3 enhanced both CD4+ and CD8+ 
TIL density (figure 1K,L), but not of FoxP3+ Treg cells 
(figure 1M,N), which led to a higher CD8+:FoxP3+ cell 
ratio in Ad- SOD3- injected than in Ad- C- injected tumors 
(figure 1O). Baseline T cell infiltration was comparable 
in Ad- C- injected, Doxo- treated (figure 1I) and untreated 
LLC tumors (online supplementary figure S1); this 
suggested that the Doxo- induced immune response is not 
sufficient to boost T cell extravasation in tumors in the 
absence of SOD3 overexpression.
As lovastatin (Lov) upregulates SOD3 in the TME,21 30 
to further confirm the SOD3 effect on TIL density, we 
implanted LLC tumors in WT and SOD3−/− mice, followed 
by Doxo and Lov treatment. As predicted,21 Lov treatment 
induced SOD3 expression in LLC tumors implanted in 
WT mice (online supplementary figure S2B) and was asso-
ciated with increased T cell but not CD11b+ cell infiltra-
tion (online supplementary figure S2C–F). Lov increased 
T cell infiltration only in WT- grafted tumors, which indi-
cated that the effect was mediated by SOD3 expression. 
The extremely low SOD3 levels in LLC tumors implanted 
in vehicle- treated WT mice might explain the lack of 
differences in intratumor T cell number compared with 
tumors grafted in SOD3−/− mice. Genetic or pharma-
cological upregulation of SOD3 in the TME therefore 
promotes selective tumor infiltration by T cells.
sod3 increases the effectiveness of anti-tumor t cell adoptive 
transfer
Since SOD3 overexpression or Lov treatment increases 
Doxo absorption into the tumor parenchyma,21 30 enhance-
ment of TIL in SOD3- overexpressing tumors might be a 
collateral effect of boosted anti- tumor immune responses 
bound to Doxo treatment. To link SOD3 directly to 
enhanced T cell extravasation, we performed adoptive 
transfer of ovalbumin (OVA)−specific, naïve CD8+ (OT- I) 
transgenic T cells to mice engrafted with mock- or SOD3- 
overexpressing EG7 thymomas, which also express OVA 
(figure 2A). EG7- SOD3 and EG7- mock cells proliferated 
equally in vitro (online supplementary figure S3), and 
tumor growth kinetics were similar in mice that did not 
receive OT- I cells (figure 2B). Adoptive transfer of OT- I 
cells restricted EG7- SOD3 growth more efficiently than 
that of EG7- mock tumors (figure 2C,D). Indeed, OT- I cell 
transfer increased survival only in mice engrafted with 
EG7- SOD3 but not with EG7- mock cells (figure 2D), and 
this was associated with an increase in intratumor OT- I 
cells (figure 2E).
The enhanced anti- tumor effect observed in SOD3- 
overexpressing tumors might be solely a result of increased 
OT- I infiltration, but could also due to improved cytolytic 
activity of OT- I TIL. To discriminate between these possi-
bilities, we analyzed the correlation between intratumor 
OT- I cell number and tumor size. OT- I TIL numbers 
correlated inversely with tumor volume in both groups 
(EG7- mock: r2=0.808, p=0.006; EG7- SOD3: r2=0.773, 
p=0.009; figure 2F), which suggests that SOD3 overex-
pression did not alter OT- I effector activity, but only their 
arrival to the tumor.
Histochemical analyses showed higher SOD3 levels in 
EG7- SOD3 than in EG7- mock tumors (figure 2G); unex-
pectedly, this tumor- produced SOD3 accumulated near 
CD31+ structures. To determine the relevance of peri-
vascular SOD3 accumulation for TIL density, we crossed 
loxP- SOD3KI mice21 with mice expressing Tie2- Cre, 
which drive SOD3 expression to the endothelium. 
Tie2- Cre+ (SOD3 overexpression in EC; SOD3EC- Tg) or 
negative (SOD3Cre−) littermates were inoculated with EG7 
cells, after which OT- I cells were transferred to tumor- 
bearing mice (figure 2H). Perivascular SOD3 expres-
sion was found in ~55% of CD31+ structures in tumors 
implanted in SOD3EC- Tg mice, whereas SOD3 was almost 
undetectable in tumors from SOD3Cre− mice (figure 2I). 
OT- I transfer reduced tumor growth more efficiently in 
SOD3EC- Tg (8/9) than in SOD3Cre− mice (3/9; figure 2J), 
which increased the survival of the former (figure 2K). 
This anti- tumor effect was associated with enhanced OT- I 
cell infiltration in SOD3- expressing tumors (figure 2L). 
These results suggest that SOD3 abundance in the TME, 
and particularly in the perivascular region, directly deter-
mines TIL density and thus the efficacy of adoptively 
transferred tumoricidal T lymphocytes.
sod3–hIF-2α pathway regulates t cell transmigration
Analysis of selected chemokines and cytokines in cultured 
1G11- mock and 1G11- SOD3 cell supernatants showed no 
major differences, with the exception of a slight decrease 
in macrophage colony- stimulating factor (M- CSF) and 
CCL2 levels, and a slight increase in tissue inhibitor of 
metalloprotease (TIMP)−1 associated to SOD3 overex-
pression (online supplementary figure S4A,B). M- CSF 
and CCL2 might be implicated in myeloid cell migration 
and/or expansion,31 32 whereas TIMP-1 could inhibit 
lymphocyte infiltration.33 34 Of the CXCR3 ligands, only 
CXCL10 was slightly repressed in 1G11- SOD3 compared 
with 1G11- mock cells (online supplementary figure S4A); 
CXCL9 and CXCL11 were not detected. qPCR analyses 
confirmed downregulation of CXCL10 and CCL2 but 
upregulation of CXCL1 mRNA in SOD3- expressing cells 
(online supplementary figure S4C). Adhesion molecules 
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Figure 2 SOD3 fosters tumor- specific T lymphocyte infiltration. (A) Scheme of the tumor- specific CD8+ T cell adoptive transfer 
model; i.v., intravenous. (B, C) Growth kinetics of EG7- mock- induced or EG7- SOD3- induced tumors adoptively transferred with 
OT- I T- cells (C; arrow) or not (B) (n=7 mice/group). A representative experiment is shown (n=2). (D) Survival curves for the mice 
evaluated in (B, C). Curves of mice that did not receive OT- I cells are shown as dotted lines. The p values of the log- rank test for 
the comparisons are indicated. (E) Normalized number of OT- I cells infiltrating EG7- mock and EG7- SOD3 tumors, as determined 
by FACS. (F) Linear regression analyses showing the correlation between OT- I TIL and the volume for EG7- mock and EG7- 
SOD3 tumors. (G) SOD3 (red) and CD31 (green) staining from tumors in (A); nuclei were DAPI stained (blue). (H) Scheme of the 
OT- I adoptive transfer protocol in the EC- specific SOD3 transgenic (SOD3EC- Tg) mouse model. (I) Staining for SOD3 (red) and 
CD31 (green) in EG7 tumors; nuclei in blue (n=7/condition). (J) Growth kinetics of EG7- induced tumors implanted in control 
(SOD3Cre−) and SOD3EC- Tg mice. OT- I transfer is indicated (arrow) (n=9 mice/group). A representative experiment is shown (n=2). 
(K) Survival curves for the mice evaluated in (J). The p value of the log- rank test is indicated. (L) Normalized number of OT- I cells 
(×103) infiltrating EG7 tumors from mice in (J). Mean±SEM and individual values are shown; *p<0.05, two- tailed Student’s t-test.
necessary for leukocyte diapedesis, such as intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1), showed no differential expres-
sion between 1G11- mock and 1G11- SOD3 cells (online 
supplementary figure S4D).
We also analyzed CXCR3 ligand expression in tumor 
models in which SOD3 augmented T cell infiltration in 
vivo. In the LLC model (figure 1E), Ad- SOD3- injected 
tumors showed higher CXCL9 mRNA levels than those 
from Ad- C- injected tumors; CXCL10 and CXCL11 did not 
differ (online supplementary figure S4E). In contrast, 
none of the CXCR3 ligands changed significantly in 
OT- I- transferred tumors implanted in SOD3Cre− and 
SOD3EC- Tg mice (online supplementary figure S4F), 
although OT- I infiltration was significantly higher in 
the latter (figure 2L). These results could indicate that 
CXCR3 ligands are not necessary mediators of the SOD3 
effect on TIL infiltration.
Since SOD3 triggers HIF-2α stabilization,21 we analyzed 
HIF-2α involvement in selective T cell transmigration. 
HIF-2α overexpression in EC enhanced (figure 3A–C), 
whereas HIF-2α silencing restrained transmigration 
of CD4+ and CD8+ T cells (figure 3D–F). These find-
ings indicate an EC- autonomous SOD3 effect on T cell 
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Figure 3 SOD3 enhances T cell transmigration through HIF-2α. (A) HIF-2α staining in 1G11- mock and 1G11- HIF-2α-
overexpressing cells (n=10/condition). (B) Representative immunoblots of cells as in (A), hybridized with anti- HIF-2α and anti-
β-actin antibodies. The HIF-2α:β-actin ratio (mean±SEM) is shown at bottom (n=3). (C) CCL19- induced CD4+ and CD8+ T cell 
transmigration through mock- and HIF-2α-overexpressing 1G11 monolayers (n=6). (D) HIF-2α staining in shNT- transfected and 
shHIF-2α-transfected 1G11 cells (n=12/condition). (E) Determination of HIF-2α levels in total lysates from shNT- transfected and 
shHIF-2α-transfected 1G11 cells. The HIF-2α:actin ratio is shown at bottom (n=3). (F) CCL19- induced transmigration of CD4+ 
and CD8+ T cell through 1G11- shNT and HIF-2α-silenced 1G11 monolayers (n=6). (G) Scheme of the tumor- specific CD8+ T cell 
adoptive transfer model used in mice with tamoxifen- inducible HIF-2α deletion in EC (HIF-2αEC- KO). (H) Normalized number of 
OT- I cells infiltrating EG7 tumors from mice as in (G) (n=7 mice/group from two independent experiments). (I) Tumor model used 
for analysis of the immune infiltrate in HIF-2αEC- KO after induction of immunogenic cell death by Doxo injection. (J) Quantification 
of TIL (CD3+ cells) in LLC tumors grown in control (HIF-2αf/f) and HIF-2αEC- KO mice (n=12 fields/condition; n=4 mice/group). (K) 
Micrographs showing CD4+ (green) and CD8+ (red) infiltrating cells in LLC tumors from (J); nuclei were DAPI stained (blue). (L) 
Quantification of images from (K) (n=13 fields/condition; n=4 mice/group). *p<0.05, **p<0.01, ***p<0.001, two- tailed Student’s 
t-test.
transmigration mediated by HIF-2α levels. To place 
HIF-2α unequivocally downstream of SOD3 in the regu-
lation of T cell transmigration in vivo, we analyzed the 
infiltration of adoptively transferred, antigen- activated 
OT- I cells into EG7- SOD3 tumors implanted in mice with 
endothelial deletion of HIF-2α (HIF-2αEC- KO)21 or control 
(HIF-2αf/f) littermates (figure 3G). We found reduced 
infiltration of activated OT- I cell in tumors grafted in 
HIF-2αEC- KO mice compared with controls (figure 3H). 
In addition, we retrospectively analyzed TIL density in 
Ad- SOD3- injected, Doxo- treated LLC tumors grafted in 
HIF-2αEC- KO or HIF-2αf/f mice (figure 3I). In this model, 
Ad- SOD3 injection increases Doxo anti- tumor effective-
ness in tumors implanted in HIF-2αf/f mice, but not 
when grafted in HIF-2αEC- KO mice.21 IHC analyses with 
anti- CD3, anti- CD4, and anti- CD8 antibodies showed 
reduced TIL density in tumors grafted in HIF-2αEC- KO 
mice compared with those grafted in HIF-2αf/f litter-
mates (figure 3J–L). These data suggest that endothelial 
HIF-2α is a necessary mediator of SOD3 to increase TIL 
numbers.
sod3–hIF-2α upregulates Wnt ligands in eC
In normoxia, SOD3 stabilizes HIF-2α but not HIF-1α.21 
A search for genes whose expression has been reported 
specifically regulated by HIF-2α identified six poten-
tial candidates (including VEC) by which SOD3 might 
regulate T cell transmigration. We focused on WNT1- 
inducible signaling pathway protein 2 (WISP2/CCN5), a 
non- conventional WNT ligand of the CCN (cysteine- rich 
61 (Cyr61/CCN1)/connective tissue growth factor (CTGF/
CCN2)/nephroblastoma overexpressed gene (NOV/
CCN3)) family, since WISP2 modifies the perivascular 
environment through its interaction with the integrin 
αvβ3
35 36; WISP2 also modulates the immune cell infiltrate 
in breast tumors,37 although to our knowledge, specific 
effects on T cell migration have not been described.
WISP2 protein (figure 4A) and mRNA (figure 4B) 
levels were higher in 1G11- SOD3 than in 1G11- mock 
cells, which suggests transcriptional regulation by SOD3. 
HIF-2α overexpression increased (figure 4C), whereas 
HIF-2α silencing reduced (figure 4D) WISP2 mRNA levels 
in 1G11 cells. In silico analyses identified four putative 
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Figure 4 SOD3 induces WNT ligand transcription in endothelial cells. (A) Time- dependent accumulation of WISP2 in the 
supernatant of 1G11- mock and 1G11- SOD3 cells as determined by ELISA (n=3). (B) Relative WISP2 mRNA levels in 1G11- 
mock and 1G11- SOD3 cells (n=6). (C) Relative WISP2 mRNA levels in 1G11- mock and HIF-2α-expressing 1G11 cells (n=3). 
(D) Relative WISP2 mRNA levels in control (shNT) and HIF-2α-silenced 1G11 cells (n=6). (E). Scheme of the WISP2 promoter 
with the four HIF-2α binding sites identified. Numbers indicate positions relative to the transcription start site; arrows indicate 
primers used for ChIP amplification. (F) ChIP analysis of WISP2 promoter in 1G11- mock and 1G11- SOD3 cells using anti- HIF-
2α antibodies. Coprecipitated DNA fragments were quantified by PCR using the primers indicated (n=3). (G, H) Relative WISP2 
mRNA levels in EG7- SOD3 tumors (G; n=7 mice/group from two independent experiments), and Ad- SOD3- injected LLC tumors 
(H; n=4 mice/group in a representative experiment) dissected from control (HIF-2αf/f) and HIF-2αEC- KO mice from the experiments 
described in figure 3G,I, respectively. (I) mRNA levels of the indicated WNT ligands in 1G11- mock and 1G11- SOD3 cells. Values 
in 1G11- mock cells were used as reference (n=3). (J, K) Relative WNT2 and WNT2b mRNA levels in HIF-2α-overexpressing (J) 
or HIF-2α-silenced (K) 1G11 cells (n=3). For RT- qPCR experiments, each data point represents the mean of a technical triplicate 
in an independent experiment or mouse. Data shown as mean±SEM; *p<0.05, **p<0.01, ***p<0.001, two- tailed Student’s t-test.
hypoxia- responsive elements (HRE) in the mouse WISP2 
promoter (figure 4E). Chromatin immunoprecipitation 
(ChIP) showed that SOD3 enhanced HIF-2α association 
to the WISP2 gene promoter −2000 region (figure 4F), 
compatible with binding to the HRE region; no enhance-
ment was found when a distal promoter region was 
analyzed. Moreover, WISP2 mRNA levels were reduced in 
EG7- SOD3 tumors grown in HIF-2αEC- KO mice compared 
with those engrafted in control mice (figure 4G); 
Ad- SOD3- injected LLC tumors grown in HIF-2αEC- KO mice 
also showed reduced WISP2 mRNA levels than controls 
(figure 4H). These results suggest a HIF-2α-dependent, 
SOD3- induced transcriptional upregulation of WISP2 in 
vitro and in vivo.
In addition to WISP2, overexpression of SOD3 in 1G11 
cells upregulated WNT2 and WNT2b (also known as 
WNT13), whereas it downregulated WNT7a mRNA levels 
(figure 4I). WNT2 and WNT2b mRNA levels were increased 
by HIF-2α overexpression and reduced in HIF-2α-si-
lenced cells (figure 4J,K). SOD3 appears to enhance 
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specific WNT ligand transcription in a HIF-2α-dependent 
manner.
sod3 activates the Wnt pathway in eC
Stabilization of β-catenin is an indicator of WNT pathway 
activation.8 Whereas CTNNB1 mRNA levels were equiv-
alent in 1G11- mock and 1G11- SOD3 cells (not shown), 
SOD3 overexpression increased protein levels of β-cat-
enin, which localized mainly to the cytosolic and juxtam-
embrane region in 1G11- SOD3 cells (figure 5A); only a 
residual fraction colocalized with DAPI in the nucleus. 
Time- dependent β-catenin degradation in cyclohexi-
mide (CHX)–treated 1G11- mock and 1G11- SOD3 cells 
confirmed the higher β-catenin levels in SOD3- expressing 
cells, although these differences, significant only at initial 
time points, were lost progressively (figure 5B). β- cat-
enin half- life was comparable between both cell types 
(3.9±0.9 hours, 1G11- mock; 5.3±1.2 hours, 1G11- SOD3; 
p=0.49, two- tailed Student’s t- test), which indicates that 
SOD3 does not affect the β-catenin degradation machinery 
directly. With the exception of AXIN2, we found no differ-
ences in the expression of well- known prototypic WNT/β-
catenin- upregulated genes such as cyclin D1 (CCND1), 
MYC, and vascular endothelial growth factor- A (VEGFA)38 
between 1G11- mock and 1G11- SOD3 cells (figure 5D). 
Transcription of all these genes was nonetheless readily 
induced in 1G11- SOD3 cells that overexpressed the 
nuclear N- terminal- truncated β-catenin mutant Δ90βcat 
(online supplementary figure S5). The lack of induction 
of canonical WNT/β-catenin genes in 1G11- SOD3 cells 
might not be an intrinsic defect, but linked to β-catenin 
retention outside the nucleus.
The WNT pathway also stabilizes the forkhead box M1 
(FoxM1) transcription factor,39 whose deficiency causes 
severe abnormalities in lung vasculature during devel-
opment.40 Total FoxM1 protein levels (figure 5E) and 
nuclear accumulation (figure 5F,G) were higher in 1G11- 
SOD3 than in 1G11- mock cells. SOD3 nonetheless did not 
alter FOXM1 mRNA levels (not shown), which suggests a 
posttranscriptional regulatory mechanism. These results 
thus indicate that SOD3 triggers some features of the 
WNT/β-catenin pathway in endothelial cells.
Wnt pathway mediates sod3-enhanced t cell transmigration
To analyze the importance of the SOD3- induced WNT 
pathway on T cell transmigration, WNT pathway was 
inhibited in 1G11- SOD3 cells by incubation with the pan- 
tankyrase inhibitor XAV-939. XAV-939 treatment reduced 
both β-catenin and FoxM1 protein levels (figure 5H), 
as well as the transmigration of CD4+ and CD8+ T cells 
(figure 5I). In contrast, WNT pathway agonism by WISP2 
stimulation of 1G11- mock cells increased β-catenin and 
FoxM1 protein levels (figure 5J), and recapitulated the 
enhanced CD4+ and CD8+ T cell transmigration observed 
following SOD3 overexpression (figure 5K).
To determine whether the WNT pathway affects the 
enhanced TIL density associated to SOD3 overexpres-
sion, we adoptively transferred activated OT- I cells in 
EG7- SOD3 tumor- bearing mice pre- treated intratumor-
ally with XAV-939 (figure 5L). SOD3 overexpression did 
not induce the WNT/β-catenin pathway in EG7 cells 
(online supplementary figure S6A); moreover, the short 
XAV-939 treatment caused no differences in tumor weight 
(online supplementary figure S6B). Compared with treat-
ment with vehicle (Vhcl), XAV-939 significantly decreased 
OT- I infiltration of EG7- SOD3 tumors (figure 5M). These 
results place WNT pathway activation as a downstream 
mediator of SOD3 that enhances T cell transmigration in 
vitro and in vivo.
sod3/hIF-2α/Wnt pathway induces laminin α4
To search for potential WNT- regulated genes that could 
affect T cell transmigration, we focused on the BM 
component LAMA4, a transcriptional target of FoxM140 
that provides permissive signals for T cell migration.17 18 
FoxM1 overexpression also upregulated LAMA4 in 1G11 
cells (online supplementary figure S7). LAMA4 mRNA 
and protein levels were higher in SOD3- expressing than 
in 1G11- mock cells (figure 6A–C). HIF-2α overexpres-
sion upregulated, whereas HIF-2α silencing reduced 
LAMA4 mRNA levels in these cells (figure 6D,E). 1G11- 
SOD3 cell treatment with XAV-399 reduced LAMA4 
mRNA and protein levels compared with Vhcl- treated 
cells (figure 6F–H). Moreover, LAMA4 mRNA levels 
were reduced in XAV-939- treated tumors compared with 
controls (figure 6I). These data suggest that SOD3 trig-
gers LAMA4 transcription in a HIF-2α-dependent and 
WNT- dependent manner.
This SOD3- induced LAMA4 expression is relevant for 
T cell transmigration since LAMA4 silencing in 1G11- 
SOD3 cells reduced CD4+ and CD8+ T cell transmigration 
compared with siNT- transfected cells (figure 6J,K). We 
also found that 1G11 monolayers seeded on laminin-411- 
coated inserts were more permissive to T cell chemotaxis 
than those on laminin-511- coated transwells (figure 6L). 
These experiments pinpoint LAMA4 as a potential SOD3 
target in enhanced transendothelial T cell migration.
We then tested whether this SOD3/HIF-2α/WNT/
LAMA4 hub correlated with TIL density in vivo by retro-
spective analysis of LAMA4 staining in some tumor 
models used during the study. Endothelial SOD3 over-
expression in EG7 tumors implanted in SOD3EC- Tg mice 
boosted infiltration of OT- I transferred cells (figure 2L); 
these tumors also showed an increase in the number of 
CD31+ structures decorated with LAMA4 compared with 
those implanted in SOD3Cre− mice (figure 6M,N). We also 
observed an association between high TIL density, SOD3 
overexpression, and strong endothelial LAMA4 staining 
in EG7- SOD3 (figure 6O,P) and Ad- SOD3- injected LLC 
tumors (figure 6Q,R), two conditions that enhanced TIL 
density (figures 2E,I). In contrast, perivascular LAMA4 
levels were low in EG7- SOD3 tumors implanted in 
HIF-2αEC- KO or XAV-939- treated mice figure 6S–V), two 
models with decreased TIL density (figures 3H and 5M). 
These data not only suggest LAMA4 induction by SOD3 
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Figure 5 SOD3- induced WNT activation mediates enhanced T cell transmigration. (A) β- Catenin localization and fluorescence 
intensity in 1G11- mock and SOD3- expressing 1G11 cells (n=5 fields/condition). (B) Immunoblots of β-catenin (up) and β-actin 
(loading control) in cycloheximide- treated 1G11- mock and 1G11- SOD3 cells (n=4). (C) β- Catenin:actin densitometry ratio 
from (B). (D) Relative expression of the prototypic WNT- regulated genes in 1G11- mock and 1G11- SOD3 cells (n=4–7). (E) 
Immunoblots of FoxM1 and β-actin (loading control) in 1G11- mock and 1G11- SOD3 cells (n=4). The densitometric FoxM1:β-
actin ratio is indicated (bottom). (F, G) Micrographs (F) and quantification (G) of nuclear FoxM1 fluorescence intensity in 1G11- 
mock and 1G11- SOD3 cells (n=7 fields/condition; >20 cells/field). Nuclei were DAPI stained (blue). (H) β-Catenin and FoxM1 
levels in Vhcl- treated or XAV-939- treated 1G11- SOD3 cells. Quantification is shown at right, with β-actin as reference (n=3). (I) 
CCL19- induced CD4+ and CD8+ T cell transmigration through Vhcl- treated or XAV-939- treated 1G11- SOD3 monolayers (n=6). 
(J) β-Catenin and FoxM1 levels in 1G11- mock cells before and after stimulation with WISP2. Quantification using β-actin as 
reference (n=3). (K) CCL19- induced CD4+ and CD8+ T cell transmigration through 1G11 monolayers stimulated or not with 
WISP2 (n=5). (L) Tumor model used to test the XAV-939 effect on SOD3- induced T cell infiltration. (M) Number of OT- I cells 
(×103) infiltrating XAV-939- treated and Vhcl- treated EG7- SOD3 tumors (n=5 mice/group; n=2). Each data point represents an 
independent measurement (A, G–K, M); for (C), data are mean±SEM of four independent experiments. For (D), each data point 
represents the mean of a technical triplicate in an independent experiment; *p<0.05, **p<0.01, ***p<0.001, two- tailed Student’s 
t-test, or two- way ANOVA with Bonferroni post hoc test (C).
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Figure 6 SOD3 effect on T cell transmigration parallels LAMA4 levels. (A, B) LAMA4 mRNA (A; n=10) and protein levels (green, 
B) in 1G11- mock and 1G11- SOD3 cells; nuclei were DAPI counterstained (blue). (C) Mean fluorescence intensity from the 
images in (B) (n=7 fields/condition). (D, E) LAMA4 mRNA levels in HIF-2α-overexpressing 1G11 cells (D) and HIF-2α-silenced 
1G11- SOD3 (E). (F) LAMA4 mRNA levels in Vhcl- treated and XAV-939- treated 1G11- SOD3 cells (n=4). (G, H) LAMA4 staining 
(red) in Vhcl- treated and XAV-939- treated 1G11- SOD3 cells; nuclei (blue); quantification in (H) (n=6 fields/condition). (I) LAMA4 
mRNA levels in XAV-939- treated and Vhcl- treated tumors, normalized to CD31 mRNA (n=5/group). (J) LAMA4 staining (red) 
in 1G11- SOD3 cells at 48 hours post- transfection with non- target (shNT) or lama4- specific (shlama4) shRNA. (K) CD4+ and 
CD8+ T cell transmigration through shNT- transfected or shlama4- transfected 1G11- SOD3 (n=7). (L) Transmigration of naïve T 
cells through 1G11 cells seeded on laminin-411 or laminin-511 (n=6). (M, N) CD31 (red), LAMA4 (green), and SOD3 (pseudo- 
color gray) in EG7 tumors implanted in SOD3Cre− and SOD3EC- Tg mice; quantification of the LAMA4/CD31 area in (N) (n=14 
fields/condition). (O, P) CD31 (green) and LAMA4 (red) in sections from EG7- mock and EG7- SOD3 tumors; LAMA4/CD31 
quantification in (P) (n=6 fields/condition). (Q, R) CD31 (red) and LAMA4 (green) staining (Q) and quantification (R; n=6 fields/
condition) in Ad- C- injected and Ad- SOD3- injected LLC tumors; nuclei (blue). (S, T) Staining of CD31 (red) and LAMA4 (green) in 
EG7- SOD3 tumors implanted in HIF-2αf/f and HIF-2αEC- KO mice; LAMA4/CD31 area quantification in (S) (n=7/condition). (U, V) 
CD31 (red) and LAMA4 (green) in XAV-939- treated and Vhcl- treated tumors; quantification of the LAMA4/CD31 area in (U) (n=7/
condition). Images from tumors were quantified from at least three mice/experimental condition; *p<0.05, **p<0.01, ***p<0.001, 
two- tailed Student’s t-test.
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in vivo, but also implicate LAMA4 as a potential mediator 
of SOD3- enhanced T cell infiltration.
sod3 correlates with Cd8+ t cell infiltration in colorectal 
carcinomas
To study whether SOD3 levels influence TIL in human 
cancers, we used a tissue microarray (TMA) of 95 primary 
stage II colorectal carcinomas (online supplementary 
table S2) from patients diagnosed between January 2000 
and December 2010. Based on ASCO and ESMO guide-
lines,41 the patients received neither neoadjuvant nor 
adjuvant chemotherapy until recurrence. Thirty patients 
relapsed (range 3–76 months), similar to recurrence in 
some studies for this tumor stage.42 We found no statis-
tically significant association between age or gender 
and disease progression; although there was a tendency 
toward association between disease progression and 
tumor grade, the number of high- grade lesions was too 
small (8) to infer statistical significance.
Although SOD3 is normally downregulated in CRC 
compared with healthy colon tissue,21 26 some tumors 
retain some SOD3 expression in the epithelial and 
stromal compartments. We determined the z- score43 for 
SOD3 staining in the TMA to classify tumors with negative 
(<140) or positive (>140) SOD3 expression, according to 
the cut- off obtained with a ROC curve. Immunohisto-
chemical analyses showed that SOD3 positivity was asso-
ciated to enhanced endothelial WNT signaling, using 
β-catenin as a readout, compared with SOD3− tumors 
(figure 7A,B). The percentage of β-catenin- stained EC 
was also higher in SOD3+ than in SOD3− tumors (n=94; 
p=0.04, Pearson’s χ2). β-catenin staining was usually 
intense in the epithelium and weak in the endothelium 
(figure 7A,B). Most tumors with high SOD3 levels showed 
intense β-catenin staining in the juxtamembrane region, 
but not in the nucleus of the tumor cells (figure 7A,B).
Analysis of the TMA also showed increased LAMA4 
staining in SOD3+ compared with SOD3− tumors 
(figure 7A). The association of SOD3 and LAMA4 staining 
involved both neoplastic and stromal cells. We found a 
median z- score value for LAMA4 of 85 (range 0–300). The 
ROC curve indicated a cut- off value of 70 to best discrim-
inate sample weighing sensitivity and specificity; based on 
this value, 48.6% of the cases were negative for LAMA4 
expression. We found a significant association between 
LAMA4+ and SOD3+ tumors (p=0.04, Pearson’s χ2), as 
well as a significant correlation between the z- scores for 
LAMA4 and SOD3 (figure 7C). In support of this asso-
ciation, LAMA4 mRNA was quantified in a cohort of 106 
patients with CRC (stages I–IV) for which SOD3 mRNA 
was previously determined.21 In contrast to published 
data,44 we found that LAMA4 mRNA was downregulated 
in CRC compared with non- tumor samples (>10 cm from 
the primary tumor; figure 7D). In this cohort, we found 
a positive correlation between LAMA4 and SOD3 mRNA 
levels in CRC samples (figure 7E). Both downregulation 
of LAMA4 mRNA and correlation with SOD3 mRNA levels 
were further validated in a second cohort comprising 90 
CRC stage III and 24 non- tumor samples (figure 7F,G). 
These results support a role for SOD3 in the transcrip-
tional regulation of LAMA4.
In the stage II CRC cohort, we observed a clear asso-
ciation between SOD3 positivity and CD8+ T cell density 
(figure 7H; online supplementary figure S8). The 
average number of intraepithelial CD8+ T cells differed 
between SOD3- positive and SOD3- negative tumors (48.57 
and 26.74, respectively; p<0.0001, two- tailed Student’s 
t- test). There was also a significant correlation between 
SOD3 z- score and intraepithelial CD8+ T cell counts 
(figure 7I), but not with CD8+ T cell density in the colon 
lamina propria (figure 7J), which suggests a specific role 
for SOD3 in intratumor T cell infiltration. The LAMA4 
z- score also correlated with intraepithelial CD8+ TIL 
counts (figure 7K), suggesting a correlation between 
LAMA4 induction and effector T cell infiltration. To vali-
date this observation, we correlated SOD3 mRNA levels 
with a T cell inflammatory signature28 in 382 CRC tumor 
samples from the TCGA. Mean SOD3 expression values 
were increased in CRC samples with high versus low T cell 
infiltration (10.17 vs 9.61; p=0.23×10−3), with a correla-
tion coefficient of 0.19.
In accordance with published data,45 our stage II CRC 
cohort also showed an association of high density of 
intraepithelial CD8+ T lymphocytes with less relapse rate 
(n=95; p=0.01, Pearson’s χ2; OR 0.3 for CD8 (95% CI 
0.1 to 0.7), p=0.05) and with extended recurrence- free 
survival (figure 7L). Extended recurrence- free survival 
was also linked to SOD3 positivity (figure 7M), consis-
tent with the SOD3/CD8+ TIL correlation (figure 7I). 
Of the 14 patients with SOD3+ tumors, only one showed 
recurrence during the follow- up period, whereas malig-
nancy recurred in 29/80 patients from the SOD3− group 
(median time to recurrence 16 months; p=0.031, Pear-
son’s χ2; OR 0.14 (95% CI 0.02 to 0.98), p=0.06). High 
LAMA4 levels tended to be associated with reduced 
relapse rate (OR 0.6 (95% CI 0.3 to 1)) and extended 
relapse- free survival (figure 7N), consistent with its associ-
ation to high CD8+ T cell density (figure 7K).
dIsCussIon
Identification of the endothelial determinants that dictate 
the trafficking of specific immune cell subtypes into the 
TME are central to the development of effective immuno-
therapies. Our data suggest that SOD3 downmodulation 
in the TME, as occurs in many human cancers,23–26 consti-
tutes an immune evasion mechanism that selectively 
hampers T lymphocyte infiltration into tumors. Rever-
sion of this situation by SOD3 re- expression in the TME 
boosted infiltration of effector T cells (but not of Treg 
or myeloid cells) and improved immunotherapy after 
adoptive transfer of tumor- specific CD8+ T cells. SOD3 
levels correlated positively with CD8+ TIL numbers and 
extended recurrence- free survival in a cohort of patients 
with primary stage II colorectal carcinoma. SOD3 might 
thus be part of a regulatory network conserved between 
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Figure 7 SOD3 associates with increased CD8+ TIL and recurrence- free survival in human colorectal cancer (CRC). (A, B) 
Representative images (×200; insets ×400) of tissue microarray (TMA) samples stained for SOD3, β-catenin, and LAMA4 
in SOD3- positive (A) and SOD3- negative (B) tumors. Panoramic views of the TMA samples (×50) are provided in online 
supplementary figure S9. (C) Correlation of estimated z- scores for SOD3 and LAMA4 in images from (A) and (B). (D) Scatter 
plot showing individual data points and mean for LAMA4 mRNA levels in non- tumor (NT; n=13) and CRC samples (n=106) 
from cohort 1. (E) Correlation of SOD3 and LAMA4 mRNA levels in the CRC cohort 1. (F) Scatter plot as above for LAMA4 
mRNA levels in the cohort 2 of 24 non- tumor and 90 CRC samples. (G) Correlation of SOD3 and LAMA4 mRNA levels in the 
CRC cohort 2. (H) Images of TMA samples stained for SOD3 and CD8, representative of SOD3- positive and negative tumors. 
(I, J) Correlation of estimated z- score for SOD3 and the number of CD8+ T cell in the epithelium (I) and the lamina propria (J). 
(K) Correlation of the LAMA4 z- score and the number of intraepithelial CD8+ TIL. (L–N) Kaplan- Meier curves for cumulative 
recurrence- free survival between patients with CRC based on intratumor CD8+ T cell counts (L), SOD3 positivity (M), or LAMA4 
staining (N). The p value of the difference for each comparison was obtained using the log- rank test. (C, E, G, I, J, K) Pearson’s r 
correlation test; (D, F) *p<0.05, **p<0.01, two- tailed Student’s t- test.
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murine and human tumors that controls intratumor T 
cell trafficking.
We propose that the SOD3 effect on TIL trafficking is 
intrinsic to the tumor- associated endothelium. In support 
of this idea, SOD3 overexpression in EC was sufficient 
to boost specific T cell transmigration in vitro, and TILs 
were reduced in SOD3- expressing tumors engrafted in 
HIF-2αEC- KO mice. Although these data imply an EC- au-
tonomous effect, the source of SOD3 nonetheless seems 
irrelevant, as SOD3 overexpression in neoplastic cells 
or EC increased CD4+ and CD8+ TIL equally. In both 
models, SOD3 was accumulated near CD31+ structures, 
which could indicate a bias for SOD3 binding to extracel-
lular matrix components of the endothelial BM. It is also 
remarkable that SOD3 did not increase CD4+ and CD8+ 
TIL in immunologically unboosted tumors (untreated 
LLC tumors). SOD3 would thus provide not an instruc-
tive but rather a permissive signal in the tumor endothe-
lium for transmigration of effector T cells.
Our mouse and cell models pinpoint activation of a 
SOD3- induced, HIF-2α-dependent WNT pathway in EC 
as central to the enhanced transendothelial T cell migra-
tion. Blockade of the WNT pathway or deletion of HIF-2α 
in EC reduced both SOD3 enhancement of T cell trans-
migration in vitro and TIL density in SOD3- expressing 
tumors. SOD3/HIF-2α appears to trigger WNT activation 
through the autocrine secretion of specific WNT ligands. 
HIF-2α also transactivates the WISP2 promoter in human 
EC,37 which suggests a common regulatory mechanism 
in humans. Analyses in human CRC support this hypoth-
esis, as SOD3 levels correlated with the percentage of 
β-catenin- stained EC.
Consistent with SOD3- induced WNT pathway activa-
tion, β-catenin protein levels were higher in 1G11- SOD3 
than in 1G11- mock cells. Nevertheless, β-catenin stabi-
lization in 1G11- SOD3 cells did not induce its massive 
nuclear translocation or a full canonical WNT/β-catenin 
transcription program. In EC, SOD3 overexpression 
increased FoxM1—another WNT target—but not β-cat-
enin nuclear accumulation; this differs from reports for 
transformed cells in which β-catenin translocates to the 
nucleus after binding to FoxM1.46 We propose that β-cat-
enin is sequestered in the junctional contacts between EC 
by VEC, which is also upregulated by SOD3/HIF-2α.21 
High VEC levels in 1G11- SOD3 would act similarly to 
E- cadherin in other cell systems,47 that is, sequestering 
β-catenin in the membrane and preventing its nuclear 
translocation. VEC might be a central regulator to the 
outcome of WNT activation in the endothelium, in a clear 
parallel to E- cadherin function in epithelial cells.48 Acti-
vation of the canonical WNT/β-catenin pathway is asso-
ciated to TIL exclusion in several human cancers,5 but 
in CRC this occurs only in tumors with nuclear β-catenin 
accumulation.28 In our stage II CRC cohort, high SOD3 
levels usually coincided with strong β-catenin staining in 
tumor cells, but it was largely excluded from the nucleus 
(figure 7A). SOD3 might boost TIL entry only in those 
tumors that have intact cytosolic β-catenin retention 
mechanisms in neoplastic and endothelial cells, thus 
preventing β-catenin signaling.48
Whereas SOD3/HIF-2α-induced VEC upregulation 
and β-catenin stabilization fit well with the reduction of 
tumor vessel leakage associated with SOD3 overexpres-
sion,21 it is intriguing that stabilization of the vascular 
adherens junctions matches increased transendothelial T 
cell migration. Redistribution and stabilization of VEC at 
the cell–cell junctions is one of the mechanisms by which 
LAMA5 restricts paracellular transmigration of leuko-
cytes.20 Transient release of VEC, p120, and β-catenin 
interactions to allow transmigration is nonetheless regu-
lated by a complex network of phosphatases, kinases, and 
adherens junction components.49 Moreover, leukocyte 
extravasation and vascular permeability are controlled by 
phosphorylation in specific tyrosine residues of VEC.50 
Future research should determine whether EC binding 
to a LAMA4- enriched BM triggers a VEC phosphoryla-
tion pattern compatible with transendothelial migration 
while maintaining reduced leakage. As an alternative, 
SOD3 might bias transcellular over paracellular T cell 
diapedesis, as reported in some circumstances.51
Our results suggest that the endothelial SOD3/HIF-2α/
WNT pathway selectively boosts T cell transmigration 
through the induction of LAMA4 expression. LAMA4 
silencing impaired T cell transmigration through 1G11- 
SOD3 monolayers, whereas LAMA4 supplementation 
increased transmigration through 1G11- mock cells. In 
vivo LAMA4 protein levels correlated positively with TIL 
density after SOD3 overexpression, but negatively after 
endothelial HIF-2α deletion or WNT pathway inhibition; 
this SOD3/LAMA4 association was also observed in three 
CRC cohorts.
The precise mechanism by which SOD3 boosts specific 
T cell entry merits, however, further research. The initial 
concept of a differential effect of LAMA4 and LAMA5 
on T cell transmigration17 is not supported by inflam-
matory mouse models, in which T cells, neutrophils, 
and monocytes extravasate preferentially at LAMA5- low 
sites.18 19 52 53 It therefore seems that the LAMA4/LAMA5 
balance is not the main cause of selective extravasation/
exclusion of T cells. The G domains of both LAMA4 and 
LAMA5 act as ligands for T cell integrins such as α6β1.54 
However, neither the specificity pattern of laminin–inte-
grin interactions nor the integrin expression pattern in 
leukocyte subsets comprehensibly explain specific trans-
migration of effector T cells into tumors. The idea that 
SOD3 boosts T cell infiltration through the upregulation 
of CXCR3 ligands, proposed to be dominant for T cell 
infiltration into tumors,9 does not match well with all 
data; although CXCL9 was associated with increased TIL 
infiltration in the LLC tumor model, this was not general 
to other tumor models. Moreover, SOD3 enhanced T cell 
transmigration in vitro without CXCR3 ligand induction. 
We propose that TIL specificity is achieved by the combi-
nation of different signals. On the one hand, LAMA4 
might provide a permissive signal used by T cells and 
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perhaps by other leukocytes to enter tumors. This initial 
signal, with the associated immune response to the tumor 
cells, would cause on the other hand upregulation of 
an instructive signal (CXCR3 ligands or another T cell 
chemoattractant), establishing a feed- forward loop that 
further enhances selective tumor infiltration by effector 
T cells.
SOD3 levels were associated with enhanced TIL 
numbers in a small cohort of patients with stage II 
CRC and with a T cell inflammatory signature in CRC 
samples from the TCGA. SOD3 positivity was also asso-
ciated with lower recurrence rates in our CRC cohort, 
although caution should be exercised due to the small 
sample size. TIL density has prognostic value for clinical 
stratification of patients with CRC,1 55 including those 
in stage II,45 as was also observed in our stage II cohort. 
The SOD3 effect on recurrence- free survival is thus 
consistent with a SOD3- induced increase in intraepi-
thelial CD8+ TIL in these tumors. High LAMA4 levels 
also correlated with enhanced CD8+ T cell counts and 
reduced recurrence rates, but the association of LAMA4 
positivity with these clinical parameters was less marked 
than that for SOD3. The relationship of LAMA4 expres-
sion with CRC outcome is inconsistent; whereas one 
study found a negative association with overall survival 
in advanced CRC,56 another did not.44 LAMA4 induces 
proliferation and migration in some cancer cell types,57 
and our IHC analyses showed that LAMA4 was also 
abundant in cancer cells and their underlying BM. It is 
possible that the LAMA4 anti- tumor signal associated to 
TIL entry could be counteracted by its pro- tumor activity 
in the neoplastic cells.
Our study raises new questions that deserve future 
research. Given the compensatory expression of 
LAMA4 and LAMA5,15 it would be interesting to 
determine whether SOD3 levels also downregulate 
LAMA5 expression in the tumor vasculature. This is 
particularly relevant, since LAMA4/LAMA5 balance is 
a molecular switch that drives immunity or tolerance 
in allograft transplants.18 In the therapeutic sphere, it 
is needed to identify treatments that increase SOD3 
levels in established tumors. Some statins upregulate 
SOD3 gene expression (21 30 and this report), but 
these drugs might have immunomodulatory effects 
incompatible with robust immunotherapeutic regi-
mens.58 It remains to be explored how SOD3 poten-
tiates other immunotherapies, including immune 
checkpoint blockers or vaccination, in addition to its 
synergism with adoptive T cell transfer reported here. 
Finally, the contrasting tumor- specific and EC- specific 
WNT activities on TIL entry determined here reveals 
an intricate network by which this pathway regulates 
immune function in the TME and also might allow 
the design of WNT- based immunotherapeutic strat-
egies by targeting WNT inhibitors to specific tumor 
compartments.
ConClusIon
Our results identify the perivascular activity of the anti- 
oxidant enzyme SOD3 as a permissive signal for selec-
tive infiltration of effector T cells into the TME, both 
in murine and in human tumors. This SOD3 effect 
relies on HIF-2α-induced WNT pathway activation in 
EC, which modifies the endothelial BM by inducing 
LAMA4, known to be involved in the maturation and 
structural integrity of microvessels.17 18 Our results iden-
tify a cell type–specific function of the WNT pathway 
in intratumor T cell infiltration and also highlight the 
endothelial BM, and particularly LAMA4 levels in this 
BM, as a potential target for effective boosting of anti- 
tumor immune responses.
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